Over 5 million New York Medicaid members to gain access to Transcranial Magnetic Stimulation (TMS) services MALVERN, Pa., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders and the maker of NeuroStar® Advanced Therapy, the leading provider of Transcranial Magnetic Simulation (TMS),... Read more
SAN DIEGO, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ: BNGO) (“Bionano” or the “Company”) today announced the closing of its previously announced public offering of an aggregate of 5,000,000 shares of the Company’s common stock (or common stock equivalents in lieu thereof), Series E warrants to purchase up to 5,000,000 shares of the Company’s common stock and short-term Series F warrants to purchase up to 5,000,000 shares of the Company’s... Read more
The Memorandum of Understanding includes the formation of a Joint Venture in the Kingdom of Saudi Arabia for manufacturing and distribution of the Company's upcoming Co-Dx™ PCR platform and other Co-Dx IP SALT LAKE CITY, Sept. 16, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that... Read more
New Study Strengthens Rationale for Spectral’s PMX Therapy by Defining Endotoxic Septic Shock (ESS) as the Highest-Risk Patient Group TORONTO, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today highlighted newly published findings in Critical Care Explorations that define endotoxic septic shock (“ESS”) as a... Read more
SAN DIEGO, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that an issue of the book series Methods in Molecular Biology dedicated to studies of the catastrophic genome rearrangement known as chromoanagenesis was published with multiple studies highlighting the advantages of optical genome mapping (OGM) in chromoanagenesis research.
According to research, chromoanagenesis refers to a catastrophic genomic event frequently associated... Read more
Definitive agreement to accelerate adoption of Renalytix's FDA-approved, Medicare reimbursed kidneyintelX.dkd test to slow kidney disease progression and improve patient outcomes
NEW YORK, Sept. 15, 2025 /PRNewswire/ -- Renalytix plc (LSE: RENX) (OTCQB: RNLXY), today announced an agreement with Tempus AI, Inc. (NASDAQ: TEM) to make kidneyintelX.dkd prognostic blood testing more widely available for eligible patients within its US network of healthcare institutions.... Read more
SAN DIEGO, Sept. 15, 2025 (GLOBE NEWSWIRE) -- Bionano Laboratories, a wholly-owned subsidiary of Bionano Genomics, Inc. (Nasdaq: BNGO) offering CLIA-certified laboratory developed tests (LDTs) based on optical genome mapping (OGM), today announced that Centers for Medicare & Medicaid Services (CMS) posted the preliminary payment determination for the Category I Current Procedural Terminology (CPT®) code for use of OGM in cytogenomic genome-wide analysis to detect structural... Read more
VANCOUVER, BC / ACCESS Newswire / September 15, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT) (OTCQB:XPHYF) (FSE:4XT) is pleased to announce the successful completion of proof-of-concept trials for its Semaglutide oral dissolvable film ("ODF") program at Vektor Pharma TF GmbH ("Vektor Pharma"), the Company's wholly owned German subsidiary.
Over the past several weeks, multiple proprietary film platforms were evaluated at Vektor Pharma. One of these... Read more
PALO ALTO, Calif. / Sep 15, 2025 / Business Wire / Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the appointment of Alex M. Azar II to its board of directors, effective immediately. As the 24th Secretary of the U.S. Department of Health and Human Services (HHS), Secretary Azar had oversight and management of agencies critical to all Americans’ health care including the Centers for Medicare and Medicaid Services, the Food and Drug... Read more
Merger to Create Combined Company Focused on Embodied AI for the Autonomous Workforce ISFIYA, ISRAEL, Sept. 12, 2025 (GLOBE NEWSWIRE) -- MBody AI (“MBody AI”) and Check-Cap Ltd. (“Check-Cap” or the “Company”) (NASDAQ: CHEK) today announced that they have entered into a definitive Agreement and Plan of Merger (the “Merger”). If the Merger is approved by Check-Cap shareholders, it will create a combined company focused on embodied AI for the autonomous... Read more
1st Half revenue grew 452.1% to $32.3 million YoY
IM8 achieved $5.9 million revenue in August 2025, representing a CAGR1 of over 3,100%
Prenetics increases FY2025 revenue guidance range of $85 – $100 million
Prenetics provides update on Bitcoin Treasury, adding a total of 228 Bitcoin, and accumulating 1 BTC daily
Prenetics to achieve break-even in Q1 2026, and EBITDA positive moving forward CHARLOTTE, N.C., Sept. 12, 2025 (GLOBE NEWSWIRE) -- Prenetics Global... Read more
SALT LAKE CITY, Sept. 11, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it has performed an in silico analysis of the primers sets used in its Co-Primers®-based PCR tests for the detection of chikungunya virus (or "CHIKV"), showing a high homology against over 1,200 CHIKV sequences and confirming... Read more
CHICAGO / Sep 11, 2025 / Business Wire / Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its updated Tempus Pixel, an AI-powered cardiac imaging platform. This update allows the generation of T1 and T2 inline maps, further enhancing the device’s capabilities for cardiac MR image analysis.
Tempus Pixel provides... Read more
Streamlined access to Guardant Shield ™ will help millions of people residing in senior living facilities to stay up to date on colorectal cancer screening
LabFlorida/SunDX will provide patients in assisted and independent living communities, as well as residential care facilities across 20 states access to Shield
LabFlorida exclusively distributing Shield in senior centers in Florida PALO ALTO, Calif. / Sep 11, 2025 / Business Wire / Guardant Health, Inc. (Nasdaq:... Read more
WILMINGTON, Mass. / Sep 11, 2025 / Business Wire / Charles River Laboratories International, Inc. (NYSE: CRL) has recently announced two strategic collaborations across its contract development and manufacturing organization (CDMO), aimed at advancing novel oncology research and development. These collaborations include forming an alliance with the Parker Institute for Cancer Immunotherapy and supporting a streamlined manufacturing process for Children’s Hospital Los Angeles’... Read more
Full portfolio of QIAstat-Dx panels now CE-IVDR certified for use in clinical syndromic testing, underscoring commitment to highest-quality diagnostics
CE-IVDR clearance granted for QIAstat-Dx Meningitis/Encephalitis (ME) Panel, sets standard with 16 targets for central nervous system infections and broadest coverage for fast and accurate diagnosis
QIAstat-Dx panels offer unique advantages, including exclusive and medically valuable targets combined with a one-step workflow... Read more
Beckman Coulter Also Announces Development of Aß-42 Research Use Only Immunoassay Test BREA, Calif., Sept. 10, 2025 /PRNewswire/ -- Beckman Coulter Diagnostics, a Danaher company and a leader in global clinical diagnostics innovation, today launched the industry's first fully automated Brain-derived Tau (BD-Tau) research use only (RUO) immunoassay test. Access BD-Tau, along with Beckman Coulter Diagnostics' expanding portfolio of neurodegenerative disease RUO... Read more
RESEARCH TRIANGLE PARK, N.C. / Sep 10, 2025 / Business Wire / IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, today announced the launch of its Clinical Trial Financial Suite (CTFS), an AI-enabled platform orchestrating all financial aspects of clinical trials. CTFS is designed to eliminate inefficiencies created by siloed systems and fragmented processes.... Read more
Only MCED test on-market to analyze multiple biomarker classes, enhancing early cancer detection
Offered as a laboratory-developed test at $689
Nationwide access enabled through Quest Diagnostics' 7,000 patient access sites MADISON, Wis. / Sep 10, 2025 / Business Wire / Exact Sciences Corp. (Nasdaq: EXAS), a leader in cancer diagnostics, today announced the launch of the Cancerguard™ test, a new multi-cancer early detection (MCED) blood test that is now available... Read more
HENDERSON, Nev., Sept. 9, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces the signing of a Research License and Exclusive Commercial Option Rights Agreement for Antiphospholipid Syndrome ("APS") with Werfen's Immunoassay Technology Center, a worldwide leader in specialized diagnostics. Full terms of the agreement are confidential.
Commenting on the agreement, Mr. Gael Forterre, Chief Commercial... Read more
Real-world evidence demonstrates PurIST’s ability to guide first-line treatment decisions and improve outcomes for patients with advanced pancreatic ductal adenocarcinoma (PDAC) CHICAGO / Sep 09, 2025 / Business Wire / Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced the publication of a study in JCO Precision Oncology validating the clinical utility of the company’s PurIST® algorithmic... Read more
bioAffinity Technologies’ noninvasive diagnostic shifted the course of care from watchful waiting for up to 5 years to confirmed malignancy and immediate treatment SAN ANTONIO / Sep 09, 2025 / Business Wire / bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company advancing noninvasive diagnostics for lung cancer and other lung diseases, today released another compelling case study in which its flagship product, CyPath® Lung, identified cancer... Read more
In the study, TissueCypher identified that 15% of patients with non-dysplastic Barrett's esophagus (NDBE) had a probability of progression that was similar to, or exceeded, progression rates associated with low-grade dysplasia (LGD); current guidelines recommend prompt intervention for LGD to prevent disease progression FRIENDSWOOD, Texas, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative... Read more
LOS ANGELES, Sept. 08, 2025 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of fully-owned and operated outpatient imaging centers, today announced that Dr. Howard Berger, President and Chief Executive Officer, Mark Stolper, Executive Vice President and Chief Financial Officer, and Mital Patel, Executive Vice President of Financial Planning & Analysis and Chief... Read more
Strategic partnership will expand Shield to PathGroup’s 15,000+ primary care and OBGYN physicians
PathGroup’s extensive network of phlebotomists and Patient Service Centers enables easier access to Shield, the more pleasant and convenient way to screen for CRC PALO ALTO, Calif. / Sep 08, 2025 / Business Wire / Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced a strategic partnership with PathGroup, one of the nation’s leading... Read more
WILMINGTON, Mass. / Sep 08, 2025 / Business Wire / Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at two upcoming investor conferences, including: Morgan Stanley 23rd Annual Global Healthcare Conference on Tuesday, September 9th, at 10:00 a.m. EDT; and
Baird 2025 Global Healthcare Conference on Wednesday, September 10th, at 9:40 a.m. EDT. Management will present an overview of Charles River’s strategic focus, business... Read more
BRANFORD, Conn. / Sep 08, 2025 / Business Wire / Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), a proteomics technology company redefining protein analysis through single-molecule detection, today announced the launch of the V4 Sequencing Kit. The new kit is compatible with both the Platinum® and Platinum® Pro instruments.
The V4 Sequencing Kit improves sequencing coverage with the addition of glycine (G) recognition, enhanced... Read more
New study presented at HRX Live 2025 demonstrates continued advancement of company’s AI program
HeartBeam's AI algorithm performed equally well on HeartBeam 3D ECG system and standard 12L ECGs in classifying atrial fibrillation, atrial flutter and sinus rhythm
Deep learning algorithms to be used for future FDA submissions to enhance product offerings SANTA CLARA, Calif. / Sep 08, 2025 / Business Wire / HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company... Read more
GUANGZHOU, China, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today reported financial results for the three months ended June 30, 2025.
Second Quarter 2025 Financial Results
Total Revenues were RMB148.5 million (US$20.7 million) for the three months ended June 30, 2025, representing... Read more
SALT LAKE CITY, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced The Lancet Oncology published a study highlighting the performance of Myriad’s molecular residual disease (MRD) test, Precise® MRD, in patients with oligometastatic clear-cell renal cell carcinoma (ccRCC).
One of the goals of this study was to determine whether patients with oligometastatic ccRCC could... Read more
New Service Empowers Clinicians with Personalized Insights from Coriell Life Sciences to Optimize Prescribing Across Specialties SECAUCUS, N.J., Sept. 4, 2025 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced an advanced pharmacogenomic (PGx) laboratory test service designed to help providers understand the patient's individual genetic response to select drug therapies. This innovative... Read more
Tempus’ generative AI-enabled clinical assistant is designed to support providers in unlocking new insights and efficiencies CHICAGO / Sep 04, 2025 / Business Wire / Northwestern Medicine and Tempus AI, Inc. (NASDAQ: TEM) today announced a notable expansion of their longstanding collaboration. Northwestern Medicine will be the first health system to integrate David, Tempus’ generative-AI clinical co-pilot, within its electronic health record (EHR) platform for its... Read more
Latest algorithm (Shield V2) has sensitivity of 84% for colorectal cancer with specificity of 90%, with stage I sensitivity of 62%
Performance of the Shield algorithm was validated in expanded clinical cohort derived from landmark ECLIPSE study PALO ALTO, Calif. / Sep 04, 2025 / Business Wire / Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced a positive clinical readout update assessing the performance of the latest colorectal... Read more
DUBLIN / Sep 04, 2025 / Business Wire / ICON plc (NASDAQ: ICLR), a world-leading clinical research organisation, today announced that Dr. Steve Cutler has informed the Board of his decision to retire as Chief Executive Officer and the Board has appointed Mr. Barry Balfe, ICON’s Chief Operating Officer, to succeed Dr. Cutler as Chief Executive Officer effective 1 October 2025. Mr. Balfe has also been appointed to the Board. Dr. Cutler will continue to serve on the Board... Read more
Results published in the Journal of Clinical Psychopharmacology SALT LAKE CITY, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced the publication of a new meta-analysis of six prospective controlled studies1 that included 3,532 adults with major depressive disorder (MDD). The meta-analysis showed that when GeneSight® Psychotropic test results were available... Read more
Illumina Protein Prep can measure 9500 unique human protein targets, offering new insights into protein biology to fuel novel discovery for treatment of disease
Following early access program, customers commend scale, high consistency, and easy sample to insights workflow
Launch follows Illumina's announcement of agreement to acquire SomaLogic SAN DIEGO, Sept. 3, 2025 /CNW/ -- Illumina Inc. (NASDAQ: ILMN) today announced the launch of Illumina Protein... Read more
New addition to PacBio Compatible program enables scientists to connect genetic variation with gene regulation in a single assay, advancing research in rare disease and cancer MENLO PARK, Calif., Sept. 03, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced that EpiCypher, a recognized leader in epigenetics tools, has joined the PacBio Compatible program. The partnership brings... Read more
SANTA CLARA, Calif. / Sep 03, 2025 / Business Wire / Agilent Technologies Inc. (NYSE: A) today announced its participation as a premium sponsor at the upcoming European Congress of Pathology (ECP) 2025, taking place in Vienna, Austria, from September 6–10, 2025. Agilent will spotlight the European launch of its newly expanded Dako Omnis Family of instruments.
The Dako Omnis family, including the Dako Omnis 110, 165, and 165 Duo models, is built to provide flexibility,... Read more
Partnership aimed at improving cell separation and increasing cell viability WILMINGTON, Mass. / Sep 03, 2025 / Business Wire / Charles River Laboratories International, Inc. (NYSE: CRL) and Akadeum Life Sciences, a leader in advanced cell separation technologies, announced today the integration of Akadeum’s GMP-grade Human T Cell Leukopak Isolation Kit into Charles River’s Cell Therapy Flex Program.
Charles River’s Cell Therapy Flex Platform originated as an... Read more
SOUTH SAN FRANCISCO, Calif. / Sep 03, 2025 / Business Wire / Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced that Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience, will present at the Baird 2025 Global Healthcare Conference on Tuesday, September 9, 2025 at 9:40 am Eastern Time in New York City. The company will also host one-on-one meetings at the Morgan Stanley 23rd Annual Global Healthcare Conference... Read more
U.S. patent protection covers computer-aided diagnosis (“CADx”) with breast CT
Izotropic holds the exclusive rights to this patent and breast CT technology under global license agreement
CADx upgrade to be integrated into IzoView Breast CT post-initial market launch, feature may be offered as an upgrade incentive to early adopters VANCOUVER, British Columbia, and SACRAMENTO, Calif., Sept. 03, 2025 (GLOBE NEWSWIRE) -- via IBN – Izotropic Corporation... Read more
CLEVELAND, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Sotera Health Company (Nasdaq: SHC) (the “Company”) today announced the launch of a secondary offering (the “Offering”) of 20,000,000 shares of its common stock, par value $0.01 per share. All 20,000,000 shares are being offered for sale by certain affiliates of Warburg Pincus LLC (“Warburg Pincus”) and GTCR LLC (“GTCR”) as selling stockholders. No other entities, and no individuals, are selling shares... Read more
BEDFORD, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced Brian Markison, Chief Executive Officer, will present at the Morgan Stanley 23rd Annual Global Healthcare Conference at 7:00 a.m. ET on Tuesday, September 9.
To access the live webcast of the presentation,... Read more
SOUTH SAN FRANCISCO, Calif. / Sep 02, 2025 / Business Wire / Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced that it has collaborated with next generation therapeutics company, Synthetic Design Lab (SDL).
“With our high throughput expertise, from novel binder discovery services to high throughput screening capabilities, we’re able to support researchers working to unlock novel engineered therapeutics,” said Emily... Read more
SANTA CLARA, Calif. / Sep 02, 2025 / Business Wire / Agilent Technologies Inc. (NYSE: A) today announced that its MMR IHC Panel pharmDx (Dako Omnis) has received class C companion diagnostic (CDx) certification under EU in vitro diagnostic regulation (IVDR)1 as a CDx test for colorectal cancer. MMR IHC Panel pharmDx (Dako Omnis) is indicated as an aid to identify mismatch repair (MMR) deficient CRC patients eligible for treatment with OPDIVO® (nivolumab) in combination with... Read more
BERKELEY, Calif. and MAINZ, Germany, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announces today that ColoAlert® has received official registration with the Medicines and Healthcare products Regulatory Agency (MHRA) and is now authorized for marketing in the United Kingdom.
This milestone follows the technology partnership... Read more
New customer launches representing 107,000 lives covered reinforce Dario's B2B2C momentum and recurring revenue growth
Dario's multi-condition digital health solutions deliver real-time results for prediabetes, diabetes, and hypertension resulting in a 23% reduction in hospitalizations, 9% reduction in healthcare utilization, and $5,000 reduction in employer costs per user
80% of the new accounts signed in 2025 are for multi-condition programs
Pipeline of commercial... Read more
Majority of fentanyl positives also contain other drugs, with co-positivity with marijuana doubling since 2020 SECAUCUS, N.J., Sept. 2, 2025 /PRNewswire/ -- The percentage of employees in the general U.S. workforce testing positive for fentanyl in random drug tests far exceeded those in pre-employment testing, according to the 2025 Quest Diagnostics Drug Testing Index™ from Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services.
The... Read more
VANCOUVER, BC / ACCESS Newswire / September 2, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT) (OTC PINK:XPHYF) (FSE:4XT) is pleased to announce the receipt of the Semaglutide active pharmaceutical ingredient (API), enabling the initiation of laboratory-scale formulation and testing of the Company's oral dissolvable film (ODF) delivery system.
In collaboration with its qualified supply partners, BioNxt has secured high-purity Semaglutide as the central... Read more
U.S. market entry set to begin for QIAstat-Dx Rise – a version of QIAstat-Dx for syndromic testing that combines unparalleled throughput with the easiest workflow
QIAstat-Dx Rise launch can process up to 160 samples per day, initial launch includes Respiratory Panel Plus and Respiratory Panel Mini and additional panels in development
Expansion of QIAstat-Dx instrument portfolio in the U.S. builds on the availability of both system options in Europe and other regions... Read more
